GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Capex-to-Operating-Income

Argos Therapeutics (FRA:77AA) Capex-to-Operating-Income : 0.00 (As of Sep. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Argos Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Argos Therapeutics's Capital Expenditure for the three months ended in Sep. 2018 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2018 was €-4.37 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Argos Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Argos Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argos Therapeutics Capex-to-Operating-Income Chart

Argos Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - -

Argos Therapeutics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Argos Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Argos Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argos Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argos Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Argos Therapeutics's Capex-to-Operating-Income falls into.



Argos Therapeutics Capex-to-Operating-Income Calculation

Argos Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2017 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-3.105) / -26.989
=N/A

Argos Therapeutics's Capex-to-Operating-Income for the quarter that ended in Sep. 2018 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -4.365
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argos Therapeutics  (FRA:77AA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Argos Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Argos Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Argos Therapeutics (FRA:77AA) Business Description

Traded in Other Exchanges
N/A
Address
4233 Technology Drive, Durham, NC, USA, 27704
Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

Argos Therapeutics (FRA:77AA) Headlines

No Headlines